| Use of prior information to stabilize a population data analysis PO Gisleskog, MO Karlsson, SL Beal Journal of pharmacokinetics and pharmacodynamics 29, 473-505, 2002 | 174 | 2002 |
| A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α‐reductase inhibitors GI198745 and finasteride PO Gisleskog, D Hermann, M Hammarlund‐Udenaes, MO Karlsson Clinical Pharmacology & Therapeutics 64 (6), 636-647, 1998 | 90 | 1998 |
| Dopamine D2 Occupancy as a Biomarker for Antipsychotics: Quantifying the Relationship with Efficacy and Extrapyramidal Symptoms R de Greef, A Maloney, P Olsson-Gisleskog, J Schoemaker, J Panagides The AAPS journal 13, 121-130, 2011 | 72 | 2011 |
| Population pharmacokinetics of rilotumumab, a fully human monoclonal antibody against hepatocyte growth factor, in cancer patients M Zhu, S Doshi, PO Gisleskog, KS Oliner, JJP Ruixo, E Loh, Y Zhang Journal of Pharmaceutical Sciences 103 (1), 328-336, 2014 | 69 | 2014 |
| Population pharmacokinetics meta-analysis of recombinant human erythropoietin in healthy subjects P Olsson-Gisleskog, P Jacqmin, JJ Perez-Ruixo Clinical pharmacokinetics 46, 159-173, 2007 | 65 | 2007 |
| Absolute bioavailability of nicotine applied to different nasal regions CJ Johansson, P Olsson, M Bende, T Carlsson, PO Gunnarsson European journal of clinical pharmacology 41, 585-588, 1991 | 63 | 1991 |
| Intravenous nicotine retards transdermal absorption of nicotine: Evidence of blood flow–limited percutaneous absorption NL Benowitz, P Jacob III, P Olsson, CJ Johansson Clinical Pharmacology & Therapeutics 52 (3), 223-230, 1992 | 62 | 1992 |
| The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination PO Gisleskog, D Hermann, M Hammarlund‐Udenaes, MO Karlsson British journal of clinical pharmacology 47 (1), 53-58, 1999 | 61 | 1999 |
| Rilotumumab exposure–response relationship in patients with advanced or metastatic gastric cancer S Doshi, PO Gisleskog, Y Zhang, M Zhu, KS Oliner, E Loh, JJP Ruixo Clinical Cancer Research 21 (11), 2453-2461, 2015 | 45 | 2015 |
| Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population … UG Eriksson, JW Mandema, MO Karlsson, L Frison, PO Gisleskog, ... Clinical pharmacokinetics 42, 687-701, 2003 | 45 | 2003 |
| Modelling and simulation to improve decision‐making in clinical development CF Burman, B Hamrén, P Olsson Pharmaceutical Statistics 4 (1), 47-58, 2005 | 40 | 2005 |
| Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate C Falcoz, SM Kirby, J Smith, P Olsson, GP Ventresca Eur Respir J 9 (suppl 23), 162S, 1996 | 35 | 1996 |
| Disposition of inhaled 1, 1, 1, 2-tetrafluoroethane (HFA134A) in healthy subjects and in patients with chronic airflow limitation. Measurement by 18F-labeling and whole-body … VW Pike, FI Aigbirhio, CA Freemantle, BC Page, CG Rhodes, SL Waters, ... Drug metabolism and disposition 23 (8), 832-839, 1995 | 25 | 1995 |
| Validation of a population pharmacokinetic/pharmacodynamic model for 5α-reductase inhibitors PO Gisleskog, D Hermann, M Hammarlund-Udenaes, MO Karlsson European journal of pharmaceutical sciences 8 (4), 291-299, 1999 | 24 | 1999 |
| Population pharmacokinetics and pharmacodynamics of the calcimimetic etelcalcetide in chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis P Chen, P Olsson Gisleskog, JJ Perez‐Ruixo, J Xiao, J Wilkins, ... CPT: pharmacometrics & systems pharmacology 5 (9), 484-494, 2016 | 16 | 2016 |
| GR106642X, a non-chlorinated propellant for use in metered-dose inhalers: safety, tolerability and pharmacokinetics in healthy volunteers LH Denyer, SM Kirby, P Olsson, GP Ventresca Br J Clin Pharmacol 37 (Suppl.), 509P-510P, 1994 | 12 | 1994 |
| Nicotine population pharmacokinetics in healthy smokers after intravenous, oral, buccal and transdermal administration PO Olsson Gisleskog, JJ Perez Ruixo, Ĺ Westin, AC Hansson, PA Soons Clinical pharmacokinetics 60, 541-561, 2021 | 11 | 2021 |
| Exposure-response (ER) analysis of rilotumumab (R, AMG 102) plus epirubicin/cisplatin/capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric or … M Zhu, R Tang, S Doshi, KS Oliner, S Kathman, PO Gisleskog, S Dubey, ... Journal of Clinical Oncology 30 (15_suppl), 2535-2535, 2012 | 10 | 2012 |
| Prediction of survival benefit of filgrastim in adult and pediatric patients with acute radiation syndrome J Harrold, PO Gisleskog, JJ Perez‐Ruixo, I Delor, A Chow, P Jacqmin, ... Clinical and Translational Science 13 (4), 807-817, 2020 | 9 | 2020 |
| Population pharmacokinetic and pharmacodynamic modeling of etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis P Chen, A Narayanan, B Wu, PO Gisleskog, JP Gibbs, AT Chow, ... Clinical pharmacokinetics 57, 71-85, 2018 | 9 | 2018 |
Juan Jose Perez RuixoJanssen Research & DevelopmentVerified email at its.jnj.com
